Leerink Partners maintains positive outlook on United Therapeutics stock

Leerink Partners reaffirmed its Outperform rating for United Therapeutics (UTHR) with a $418 price target, citing optimism for the Phase 3 TETON-2 trial readout for idiopathic pulmonary fibrosis (IPF) in the second half of 2025, driven by significant unmet needs in the IPF market. Despite legal setbacks from Liquidia's Yutrepia launch, United Therapeutics reported strong Q1 earnings with 17% year-over-year revenue growth to $794.4 million, fueled by Tyvaso demand, leading BofA Securities to raise its stock target to $321.

Analysis

Leerink Partners has reaffirmed an Outperform rating and a $418.00 price target for United Therapeutics Corp. (UTHR), underscoring optimism surrounding the upcoming Phase 3 TETON-2 trial readout for Tyvaso in idiopathic pulmonary fibrosis (IPF) anticipated in the second half of 2025. This positive outlook is supported by the company's exceptionally strong financial position, highlighted by a perfect Piotroski Score of 9 and an "Excellent" financial health rating from InvestingPro, complemented by impressive gross profit margins of 89% and revenue growth approaching 20% over the last twelve months. Key opinion leaders emphasize a significant unmet medical need within the IPF market, noting that existing standard of care treatments like Ofev and Esbriet are tolerated by only approximately one-third of patients, thereby creating a substantial opportunity for Tyvaso as an inhaled therapy. United Therapeutics demonstrated robust performance in its first-quarter earnings, with revenue reaching $794.4 million, a 17% year-over-year increase that surpassed expectations, leading BofA Securities to raise its stock target to $321. While InvestingPro analysis suggests UTHR may be undervalued relative to its Fair Value, the company faces competitive and legal pressures, notably from Liquidia Technologies (LQDA), which has secured legal victories paving the way for the launch of its lung-disease drug, Yutrepia. Despite these legal setbacks for UTHR, analysts such as TD Cowen maintain a Buy rating, citing confidence in the company's ongoing projects, including its xenotransplantation platform, indicating continued belief in UTHR's growth trajectory.

Key Decisions for Investors

• Investors should consider the significant upside potential for United Therapeutics linked to the Phase 3 TETON-2 trial results for Tyvaso in IPF, expected in H2 2025, given the drug's potential to address a large unmet medical need.
• Evaluate United Therapeutics' current valuation in the context of its strong financial health, evidenced by a Piotroski Score of 9, 89% gross profit margins, and nearly 20% LTM revenue growth, alongside an InvestingPro indication that it may be undervalued.
• Closely monitor developments related to Liquidia Technologies' launch of Yutrepia and ongoing legal proceedings, as these represent key competitive risks that could impact United Therapeutics' market share in the pulmonary disease space, despite its current operational strength and positive analyst sentiment.